A year in data: Low value M&A activity in 2023
The inflationary pressures and a risk-averse mindset of financiers resulted in a decrease in the deal values of M&As in 2023.
20 December 2023
20 December 2023
The inflationary pressures and a risk-averse mindset of financiers resulted in a decrease in the deal values of M&As in 2023.
The pivotal trial for Ablative’s Peregrine system met its primary endpoint in patients with uncontrolled hypertension.
The trial, comparing Sight Sciences’s TearCare device to Restasis, will now join the two cohorts ahead of crossover results expected by the end of 2024.
Telix Pharmaceuticals aims for US commercial availability next year, pending regulatory approval from the US Food and Drug Administration (FDA) .
Through the phased expansion, additional 830,000 people will become eligible for the screening test.
The five-year distribution of the InsuJet needle-free device targets 770,000 patients with type 1 diabetics in Belgium.
The fully implantable Chronic Migraine System is designed for the head using a minimally invasive technique.
The panel utilises precise liquid chromatography combined with advanced tandem mass spectrometry testing to detect misuse of NPS.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
A comprehensive outlook for the leading players across the TMT industry, based on the key themes set to transform the industry landscape over the next two years. You will not find a better guide to technology in 2024.
Give your business an edge with our leading industry insights.